Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality Insights From the EMPA-REG OUTCOME Trial

被引：53

作者：

Savarese, Gianluigi ^{[1
]}

Sattar, Naveed ^{[2
]}

Januzzi, James ^{[3
,4
]}

Verma, Subodh ^{[5
]}

Lund, Lars H. ^{[1
]}

Fitchett, David ^{[6
]}

Zeller, Cordula ^{[8
]}

George, Jyothis T. ^{[9
]}

Brueckmann, Martina ^{[9
,10
]}

Ofstad, Anne Pernille ^{[11
]}

Inzucchi, Silvio E. ^{[12
]}

Wanner, Christoph ^{[13
]}

Zinman, Bernard ^{[7
]}

Butler, Javed ^{[14
]}

机构：

[1] Karolinska Inst, Dept Med, Cardiol Unit, Stockholm, Sweden

[2] Univ Glasgow, Glasgow, Lanark, Scotland

[3] Massachusetts Gen Hosp, Cardiol Div, Boston, MA 02114 USA

[4] Baim Inst Clin Res, Boston, MA 02114 USA

[5] St Michaels Hosp, Li Ka Shing Knowledge Inst, Div Cardiac Surg, Toronto, ON, Canada

[6] St Michaels Hosp, Div Cardiol, Toronto, ON, Canada

[7] Univ Toronto, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada

[8] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany

[9] Boehringer Ingelheim Int GmbH, Ingelheim, Germany

[10] Heidelberg Univ, Fac Med Mannheim, Mannheim, Germany

[11] Boehringer Ingelheim Norway KS, Asker, Norway

[12] Yale Univ, Yale New Haven Hosp, Sch Med, Sect Endocrinol, New Haven, CT USA

[13] Univ Hosp Wurzburg, Dept Internal Med 1, Nephrol, Wurzburg, Germany

[14] Univ Mississippi, Dept Med, Jackson, MS 39216 USA

来源：

CIRCULATION | 2019年 / 139卷 / 11期

关键词：

heart failure; hospitalization; mortality;

D O I：

10.1161/CIRCULATIONAHA.118.038339

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1458 / 1460

页数：3

共 5 条

[1]

Benjamin EJ, 2017, CIRCULATION, V135, pE146, DOI [10.1161/CIR.0000000000000485, 10.1161/CIR.0000000000000558, 10.1161/CIR.0000000000000530]

[2] Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial [J].

Fitchett, David ;

Zinman, Bernard ;

Wanner, Christoph ;

Lachin, John M. ;

Hantel, Stefan ;

Salsali, Afshin ;

Johansen, Odd Erik ;

Woerle, Hans J. ;

Broedl, Uli C. ;

Inzucchi, Silvio E. ;

Aizenberg, D. ;

Ulla, M. ;

Waitman, J. ;

De Loredo, L. ;

Farias, J. ;

Fideleff, H. ;

Lagrutta, M. ;

Maldonado, N. ;

Colombo, H. ;

Ferre Pacora, F. ;

Wasserman, A. ;

Maffei, L. ;

Lehman, R. ;

Selvanayagam, J. ;

d'Emden, M. ;

Fasching, P. ;

Paulweber, B. ;

Toplak, H. ;

Luger, A. ;

Drexel, H. ;

Prager, R. ;

Schnack, C. ;

Schernthaner, G. ;

Fliesser-Goerzer, E. ;

Kaser, S. ;

Scheen, A. ;

Van Gaal, L. ;

Hollanders, G. ;

Kockaerts, Y. ;

Capiau, L. ;

Chachati, A. ;

Persu, A. ;

Hermans, M. ;

Vantroyen, D. ;

Vercammen, C. ;

Van de Borne, P. ;

Mathieu, C. ;

Benhalima, K. ;

Lienart, F. ;

Mortelmans, J. .

EUROPEAN HEART JOURNAL, 2016, 37 (19) :1526-1534

[3] Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure [J].

Solomon, Scott D. ;

Dobson, Joanna ;

Pocock, Stuart ;

Skali, Hicham ;

McMurray, John J. V. ;

Granger, Christopher B. ;

Yusuf, Salim ;

Swedberg, Karl ;

Young, James B. ;

Michelson, Eric L. ;

Pfeffer, Marc A. .

CIRCULATION, 2007, 116 (13) :1482-1487

[4] SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review [J].

Verma, Subodh ;

McMurray, John J. V. .

DIABETOLOGIA, 2018, 61 (10) :2108-2117

[5] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes [J].